Anne-Sophie Gautron

Anne-Sophie Gautron has extensive work experience in translational sciences and gene therapy. Anne-Sophie is currently the Director Translational Sciences at SparingVision, where they develop and leads translational sciences for gene therapy products in the ocular space. Their responsibilities include overseeing preclinical and clinical bioanalytical strategy across various programs.

Previously, Anne-Sophie worked at Cellectis from 2014 to 2022 in multiple roles. As a Translational Senior Scientist, they were responsible for clinical biomarker strategy and implementation for allogeneic CAR T-cell therapy and gene therapy programs. Anne-Sophie also designed and conducted translational research projects in the context of the clinical development of UCART products. Additionally, they collaborated with internal stakeholders across different departments to address clinical questions.

During their time at Cellectis, Anne-Sophie also served as a Program Leader, focusing on UCART product development and cellular engineering for allogeneic adoptive immunotherapy. Their role involved overseeing translational research from in vitro proof of concept of CAR activity to collaboration with pre-clinical, regulatory, and clinical teams, as well as groups involved in process development and manufacturing of T-cell-based cellular therapies. Anne-Sophie was also a Project Leader, working on improving CAR T-cell therapeutic potency and safety through engineering efforts.

Prior to their work at Cellectis, Anne-Sophie was a Post-Doctoral Research Associate at Yale University School of Medicine from 2010 to 2014. Here, they studied the role of TIM proteins in maintaining immune tolerance in humans, the functional role of TIM-3 protein in the autoimmunity of Multiple Sclerosis, and the human B cell tolerance checkpoints.

Anne-Sophie also holds a PhD from Université Paris Descartes, where they conducted research on iNKT and iNKT17 cells and their roles in autoimmune and neurological diseases such as type 1 diabetes, Experimental Autoimmune Encephalomyelitis, and X-linked adrenoleukodystrophy. Anne-Sophie also studied the role of iNKT cells and the CD1d molecule in the prevention of type 1 diabetes.

Anne-Sophie Gautron obtained their Bachelor's degree in Immunology from Pierre and Marie Curie University in the year 2004. Anne-Sophie then pursued a Master of Science (MS) in Molecular and Cellular Immunology from the same university from 2004 to 2005. Following this, they furthered their education by completing a Pre-PhD program at Pierre and Marie Curie University's Pasteur Institute in Immunology from 2005 to 2006. Finally, they successfully completed their PhD in Immunology at Université Paris Cité from 2006 to 2009.